文献速递乳房整形与再造

标准保乳手术与肿瘤整形保乳手术及乳房切除即刻两期假体乳房再造的成本比较

Comparing costs of standard Breast-Conserving Surgery to Oncoplastic Breast-Conserving Surgery and Mastectomy with Immediate two-stage Implant-Based Breast Reconstruction.
PubMed 文献 · J Plast Reconstr Aesthet Surg · 2022-03-02

这项单中心回顾性队列研究纳入2014年1月至2016年12月期间接受乳腺癌手术的220例患者,比较标准保乳手术(C-BCS,74例)、肿瘤整形保乳手术(OP-BCS,78例)与乳房切除即刻两期假体乳房再造(M-IBR,68例)的成本与并发症率。结果显示C-BCS与OP-BCS、C-BCS与M-IBR的总成本差异有统计学意义,OP-BCS与M-IBR成本相当;并发症率C-BCS为5.5%、OP-BCS为17%、M-IBR为34%(p<0.01)。作者认为,从总治疗成本看OP-BCS在财务上不劣于M-IBR,而M-IBR并发症率更高。

要点

  • C-BCS组74例、OP-BCS组78例、M-IBR组68例,共220例患者纳入成本与并发症分析。
  • 总成本从高到低排序中,C-BCS与OP-BCS比较p<0.01,C-BCS与M-IBR比较p=0.04,OP-BCS与M-IBR成本相当。
  • 并发症率C-BCS为5.5%、OP-BCS为17%、M-IBR为34%(p<0.01)。

核心结论

  • 从总治疗成本看,OP-BCS在财务上不劣于M-IBR,而M-IBR术后并发症率更高。
  • 作者认为,考虑到OP-BCS患者报告结局更高且肿瘤学结局相似等其他获益,从M-IBR转向采用肿瘤整形技术的保乳手术似乎是合理的。

研究设计与样本

  • 单中心、回顾性队列研究,计算2014年1月至2016年12月期间所有接受乳腺癌手术患者的成本。
  • 通过病历回顾获取C-BCS、OP-BCS和M-IBR患者的患者、肿瘤及手术相关数据,治疗成本采用医院财务数据计算。
  • 共纳入220例患者:C-BCS组74例、OP-BCS组78例、M-IBR组68例。

主要发现

  • 总成本从高到低排序中,C-BCS与OP-BCS之间差异有统计学意义(p<0.01),C-BCS与M-IBR之间差异有统计学意义(p=0.04)。
  • OP-BCS与M-IBR的成本相当。
  • 并发症率C-BCS为5.5%,OP-BCS为17%,M-IBR为34%(p<0.01)。

临床怎么用

  • 作者认为,从总治疗成本看OP-BCS在财务上不劣于M-IBR,而M-IBR并发症率更高。
  • 作者认为,考虑到OP-BCS患者报告结局更高且肿瘤学结局相似等其他获益,从M-IBR转向采用肿瘤整形技术的保乳手术似乎是合理的。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Conventional breast-conserving surgery (C-BCS) has equal oncological outcomes and superior cosmetic and patient-reported outcomes compared to mastectomy with immediate two-stage implant-based breast reconstruction (M-IBR). Oncoplastic breast-conserving surgery (OP-BCS) is increasingly being used, as it often has better cosmetic results and it enables larger tumour resection. However, OP-BCS and M-IBR compared to C-BCS lengthens operative time and might lead to more complications and consequently to additional costs. Therefore, this study aimed to compare costs and complication rates of C-BCS, OP-BCS and M-IBR. METHODS: This single-centre, retrospective cohort study, calculated costs for all patients who had undergone breast cancer surgery between January 2014 and December 2016. Patient-, tumour- and surgery-related data of C-BCS, OP-BCS and M-IBR patients were retrieved by medical record review. Treatment costs were calculated using hospital financial data. Differences in costs and complications were analysed. RESULTS: A total of 220 patients were included: 74 patients in the C-BCS, 78 in the OP-BCS and 68 in the M-IBR group. From most expensive to least expensive, differences in total costs were found between C-BCS vs. OP-BCS and C-BCS vs. M-IBR (p=<0.01 and p=0.04, respectively). Costs of OP-BCS and M-IBR were comparable. Complication rates were 5.5% for C-BCS, followed by 17% for OP-BCS, and 34% for M-IBR (p<0.01). CONCLUSION: Considering total treatment costs, OP-BCS was financially non-inferior to M-IBR, whereas complication rates were higher following M-IBR. Therefore, when considering other benefits of OP-BCS, such as higher patient-reported outcomes and similar oncological outcomes, a shift from M-IBR to BCS using oncoplastic techniques seems justified.

来源:J Plast Reconstr Aesthet Surg,查看原文。版权归原作者所有。

引用

  1. Witmer TJK, Kouwenberg CAE, Bargon CA, et al. Comparing costs of standard Breast-Conserving Surgery to Oncoplastic Breast-Conserving Surgery and Mastectomy with Immediate two-stage Implant-Based Breast Reconstruction. J Plast Reconstr Aesthet Surg. 2022. PMID: 35398000. doi:10.1016/j.bjps.2022.02.050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。